Top

Published in:

01-06-2014 | Educational Review

Rational use of antihypertensive medications in children

Authors: Michael A. Ferguson, Joseph T. Flynn

Published in: Pediatric Nephrology | Issue 6/2014

Abstract

Hypertension has traditionally been regarded as an uncommon diagnosis in childhood and adolescence; however, there is compelling evidence to suggest that its prevalence is on the rise, particularly in those with obesity. As a result, pediatricians increasingly are asked to evaluate and manage patients with elevated blood pressure. An increased emphasis on conducting drug trials in children over the last 15 years has yielded important advances with respect to evidence-based data regarding the efficacy and safety of antihypertensive medications in children and adolescents. Unfortunately, data to definitively guide selection of initial agents is lacking. This article will present guidelines for the appropriate use of antihypertensive medications in the pediatric population, including the rational approach to selecting an appropriate medication with respect to pathophysiology, putative benefit, and likelihood for side effects.

Blumenthal S, Epps RP, Heavenrich R, Lauer RM, Lieberman E, Mirkin B, Mitchell SC, Boyar Naito V, O’Hare D, McFate Smith W, Tarazi RC, Upson D (1977) Report of the task force on blood pressure control in children. Pediatrics 59(I-II):797–820

National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRef

Sinaiko AR, Gomez-Marin O, Prineas RJ (1989) Prevalence of “significant” hypertension in junior high school-aged children: the Children and Adolescent Blood Pressure Program. J Pediatr 114:664–669PubMedCrossRef

Fixler DE, Laird WP, Fitzgerald V, Stead S, Adams R (1979) Hypertension screening in schools: results of the Dallas study. Pediatrics 63:32–36PubMed

Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ (2004) Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 113:475–482PubMedCrossRef

McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ (2007) Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr 150:640–644PubMedCrossRef

Din-Dzietham R, Liu Y, Bielo MV, Shamsa F (2007) High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation 116:1488–1496PubMedCrossRef

Muntner P, He J, Cutler JA, Wildman RP, Whelton PK (2004) Trends in blood pressure among children and adolescents. JAMA 291:2107–2113PubMedCrossRef

Boneparth A, Flynn JT (2009) Evaluation and treatment of hypertension in general pediatric practice. Clin Pediatr (Phila) 48:44–49CrossRef

10.

Yoon EY, Cohn L, Rocchini A, Kershaw D, Freed G, Ascione F, Clark S (2012) Antihypertensive prescribing patterns for adolescents with primary hypertension. Pediatrics 129:e1–e8PubMedCentralPubMedCrossRef

11.

Flynn JT (2011) Management of hypertension in the young: role of antihypertensive medications. J Cardiovasc Pharmacol 58:111–120PubMedCrossRef

12.

Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wuhl E, Zanchetti A (2009) Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 27:1719–1742PubMedCrossRef

13.

Hornsby JL, Mongan PF, Taylor AT, Treiber FA (1991) ‘White coat’ hypertension in children. J Fam Pract 33:617–623PubMed

14.

Swartz SJ, Srivaths PR, Croix B, Feig DI (2008) Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. Pediatrics 122:1177–1181PubMedCrossRef

15.

Sorof JM, Portman RJ (2000) White coat hypertension in children with elevated casual blood pressure. J Pediatr 137:493–497PubMedCrossRef

16.

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913PubMedCrossRef

17.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252PubMedCrossRef

18.

Daniels SR, Loggie JM, Khoury P, Kimball TR (1998) Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation 97:1907–1911PubMedCrossRef

19.

Sorof JM, Alexandrov AV, Cardwell G, Portman RJ (2003) Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics 111:61–66PubMedCrossRef

20.

Hanevold C, Waller J, Daniels S, Portman R, Sorof J (2004) The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. Pediatrics 113:328–333PubMedCrossRef

21.

Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Moller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650PubMedCrossRef

22.

Flynn JT, Daniels SR (2006) Pharmacologic treatment of hypertension in children and adolescents. J Pediatr 149:746–754PubMedCrossRef

23.

Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, Pezous N, Kadwa M (2011) Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 29:2484–2490PubMedCrossRef

24.

Blowey DL (2012) Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens (Greenwich) 14:383–387CrossRef

25.

Simonetti GD, Rizzi M, Donadini R, Bianchetti MG (2007) Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. J Hypertens 25:2370–2376PubMedCrossRef

26.

Woroniecki RP, Flynn JT (2005) How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol 20:791–797PubMedCrossRef

27.

Batisky DL (2012) What is the optimal first-line agent in children requiring antihypertensive medication? Curr Hypertens Rep 14:603–607PubMedCentralPubMedCrossRef

28.

Prichard BN, Cruickshank JM, Graham BR (2001) Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press 10:366–386PubMedCrossRef

29.

Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD (2012) Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 60:444–450PubMedCrossRef

30.

Garovic V, Textor SC (2005) Renovascular hypertension: current concepts. Semin Nephrol 25:261–271PubMedCrossRef

31.

Garovic VD, Textor SC (2005) Renovascular hypertension and ischemic nephropathy. Circulation 112:1362–1374PubMedCrossRef

32.

Johansson M, Friberg P (2000) Role of the sympathetic nervous system in human renovascular hypertension. Curr Hypertens Rep 2:319–326PubMedCrossRef

33.

Kenny D, Hijazi ZM (2011) Coarctation of the aorta: from fetal life to adulthood. Cardiol J 18:487–495PubMedCrossRef

34.

Gidding SS, Rocchini AP, Beekman R, Szpunar CA, Moorehead C, Behrendt D, Rosenthal A (1985) Therapeutic effect of propranolol on paradoxical hypertension after repair of coarctation of the aorta. N Engl J Med 312:1224–1228PubMedCrossRef

35.

Brili S, Tousoulis D, Antoniades C, Vasiliadou C, Karali M, Papageorgiou N, Ioakeimidis N, Marinou K, Stefanadi E, Stefanadis C (2008) Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study. J Am Coll Cardiol 51:742–749PubMedCrossRef

36.

Flynn JT, Pierce CB, Miller ER 3rd, Charleston J, Samuels JA, Kupferman J, Furth SL, Warady BA (2012) Reliability of resting blood pressure measurement and classification using an oscillometric device in children with chronic kidney disease. J Pediatr 160:434–440PubMedCentralPubMedCrossRef

37.

Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J (1996) Blood pressure and end-stage renal disease in men. N Engl J Med 334:13–18PubMedCrossRef

38.

Iseki K, Ikemiya Y, Iseki C, Takishita S (2003) Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63:1468–1474PubMedCrossRef

39.

Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A (1996) Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 11:461–467PubMedCrossRef

40.

Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939–945PubMedCrossRef

41.

The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857–1863

42.

Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73–87PubMedCrossRef

43.

Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, Warady BA (2008) Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 52:631–637PubMedCentralPubMedCrossRef

44.

Samuels J, Ng D, Flynn JT, Mitsnefes M, Poffenbarger T, Warady BA, Furth S (2012) Ambulatory blood pressure patterns in children with chronic kidney disease. Hypertension 60:43–50PubMedCentralPubMedCrossRef

45.

Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents (2011) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128 Suppl 5:S213–256

46.

Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity in the United States, 2009–2010. NCHS data brief, no. 82. National Center for Health Statistics, Hyattsville, MD. Available at http://www.cdc.gov/nchs/data/databriefs/db82.pdf. Accessed 1 February 2013

47.

Lazzeri G, Rossi S, Pammolli A, Pilato V, Pozzi T, Giacchi MV (2008) Underweight and overweight among children and adolescents in Tuscany (Italy). Prevalence and short-term trends. J Prev Med Hyg 49:13–21PubMed

48.

Valdes Pizarro J, Royo-Bordonada MA (2012) Prevalence of childhood obesity in Spain: National Health Survey 2006–2007. Nutr Hosp 27:154–160PubMed

49.

Kollias A, Skliros E, Stergiou GS, Leotsakos N, Saridi M, Garifallos D (2011) Obesity and associated cardiovascular risk factors among schoolchildren in Greece: a cross-sectional study and review of the literature. J Pediatr Endocrinol Metab 24:929–938PubMedCrossRef

50.

Midha T, Nath B, Kumari R, Rao YK, Pandey U (2012) Childhood obesity in India: a meta-analysis. Indian J Pediatr 79:945–948PubMedCrossRef

51.

Wang Y, Lobstein T (2006) Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 1:11–25PubMedCrossRef

52.

Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E (2004) Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 43:1817–1822PubMedCrossRef

53.

Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359PubMedCrossRef

54.

Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH (2008) Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. Diabetes Care 31:587–589PubMedCrossRef

55.

Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J (2013) Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the obesity society and the American Society of Hypertension. J Clin Hypertens (Greenwich) 15:14–33CrossRef

56.

Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A (2008) Renin–angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 26:831–843PubMedCrossRef

57.

Caballero AE (2003) Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11:1278–1289PubMedCrossRef

58.

Allcock DM, Sowers JR (2010) Best strategies for hypertension management in type 2 diabetes and obesity. Curr Diab Rep 10:139–144PubMedCrossRef

59.

Prabhakar SS (2013) Inhibition of renin–angiotensin system: implications for diabetes control and prevention. J Investig Med 61:551–557PubMed

60.

Sharma AM (2008) Does it matter how blood pressure is lowered in patients with metabolic risk factors? J Am Soc Hypertens 2:S23–S29PubMedCrossRef

61.

Murakami K, Wada J, Ogawa D, Horiguchi CS, Miyoshi T, Sasaki M, Uchida HA, Nakamura Y, Makino H (2013) The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO). Diab Vasc Dis Res 10:93–96PubMedCrossRef

62.

Mancia G, Grassi G, Zanchetti A (2006) New-onset diabetes and antihypertensive drugs. J Hypertens 24:3–10PubMedCrossRef

63.

Laragh JH, Sealey JE (2011) The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 24:1164–1180PubMedCrossRef

64.

Laragh J (2001) Laragh’s lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 14:837–854PubMedCrossRef

65.

Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH 3rd, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH (2009) Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 22:792–801PubMedCrossRef

66.

Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR (2010) Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 23:1014–1022PubMedCentralPubMedCrossRef

67.

Alderman MH, Cohen HW, Sealey JE, Laragh JH (2010) Pressor responses to antihypertensive drug types. Am J Hypertens 23:1031–1037PubMedCrossRef

68.

Maron BJ, Zipes DP (2005) Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. J Am Coll Cardiol 45:1318–1321PubMedCrossRef

69.

Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, Harris WA, Lowry R, McManus T, Chyen D, Whittle L, Lim C, Wechsler H (2012) Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 61:1–162PubMed

70.

Goulet C, Valois P, Buist A, Cote M (2010) Predictors of the use of performance-enhancing substances by young athletes. Clin J Sport Med 20:243–248PubMedCrossRef

71.

Fagard RH (2007) Athletes with systemic hypertension. Cardiol Clin 25:441–448PubMedCrossRef

72.

Van Baak MA (1988) Beta-adrenoreceptor blockade and exercise. An update. Sports Med 5:209–225PubMedCrossRef

73.

Van Baak MA, Koene FMM, Verstappen FTJ (1988) Exercise hemodynamics and maximal exercise capacity during beta-adrenoreceptor blockade in normotensive and hypertensive subjects. Br J Clin Pharmacol 25:169–177PubMedCentralPubMedCrossRef

74.

Vanhees L, Defoor JG, Schepers D, Lijnen P, Peeters BY, Lacante PH, Fagard RH (2000) Effect of bisoprolol and atenolol on endurance exercise capacity in healthy men. J Hypertens 18:35–43PubMedCrossRef

75.

Vehaskari VM (2009) Heritable forms of hypertension. Pediatr Nephrol 24:1929–1937PubMedCentralPubMedCrossRef

76.

Simonetti GD, Mohaupt MG, Bianchetti MG (2012) Monogenic forms of hypertension. Eur J Pediatr 171:1433–1439PubMedCrossRef

Title: Rational use of antihypertensive medications in children
Authors: Michael A. Ferguson
Joseph T. Flynn
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 6/2014
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-013-2510-z

ACC 2024 Congress

Springer Medicine

Rational use of antihypertensive medications in children

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Long-term resistance trends of uropathogens and association with antimicrobial prophylaxis

Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study

Screening blood pressure measurement in children: are we saving lives?

Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement

Rituximab fails where eculizumab restores renal function in C3nef-related DDD

Extrarenal sequential organ failure assessment score as an outcome predictor of critically ill children on continuous renal replacement therapy